|
Profile of Lung adenocarcinoma patients |
|||||
| Age/gender |
Smoker |
*FEV1% |
Tumor size (mm) |
Lymph node |
Stage |
|
|
|||||
| 80/M |
Yes |
55 |
25 |
T 1N 0 |
I a |
| 76/M |
Yes |
72 |
30 |
T 1N 0 |
I a |
| 70/F |
Yes |
48 |
24 |
T 1N 0 |
I a |
| 58/M |
Yes |
82 |
22 |
T 1N 0 |
I a |
| 62/M |
Yes |
35 |
28 |
T 1N 0 |
I a |
| 54/M |
Yes |
45 |
24 |
T 1N 0 |
I a |
| 74/F |
Yes |
85 |
32 |
T 2N 0 |
I b |
| 60/M |
Yes |
80 |
20 |
T 1N 0 |
I a |
| 68/F |
Yes |
88 |
25 |
T 1N 0 |
I a |
| 74/F |
Yes |
76 |
30 |
T 1N 0 |
I a |
| 65/F |
Yes |
82 |
15 |
T 1N 0 |
I a |
| 72/M |
Yes |
88 |
35 |
T 2N 0 |
I b |
| 54/M |
Yes |
45 |
40 |
T 2N 0 |
I b |
| 62/M |
Yes |
72 |
40 |
T 2N 0 |
I b |
| 64/M |
Yes |
62 |
35 |
T 2N 0 |
I b |
| 78/F |
Yes |
78 |
45 |
T 2N 0 |
I b |
| 45/M |
Yes |
72 |
35 |
T 2N 0 |
I b |
| 54/M |
Yes |
46 |
35 |
T 2N 0 |
I b |
| 75/M |
Yes |
72 |
35 |
T 2N 0 |
I b |
| 73/F |
Yes |
72 |
75 |
T 2N 0 |
I b |
| 72/M |
Yes |
56 |
35 |
T 2N 1 |
II b |
| 54/M |
No |
85 |
18 |
T 1N 0 |
I a |
| 68/F |
No |
106 |
15 |
T 1N 0 |
I a |
| 68/F |
No |
106 |
15 |
T 1N 0 |
I a |
| 68/F |
No |
100 |
25 |
T 1N 0 |
I a |
| 72/M |
No |
104 |
37 |
T 2N 0 |
I b |
| 78/F |
No |
112 |
45 |
T 2N 0 |
I b |
| 79/F |
No |
96 |
40 |
T 2N 0 |
I b |
| 68/M |
No |
84 |
35 |
T 2N 0 |
I b |
| 85/M |
No |
90 |
35 |
T 2N 0 |
I b |
| 78/F |
No |
96 |
24 |
T 1N 1 |
II a |
|
* = % of predicted FEV1 = forced expiratory volume in first second | |||||
Stav et al. Journal of Experimental & Clinical Cancer Research 2008 27:45 doi:10.1186/1756-9966-27-45 |
|||||